A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumors
Phase Ib/II open label, multicenter study to evaluate the efficacy and safety of AK104 (anti-PD-1 and CTLA-4 bispecific antibody) and AK117#AntiCD47 Antibody# combined with or without chemotherapy in advanced malignant tumors
Advanced Malignant Tumors
DRUG: AK104|DRUG: AK117|DRUG: Capecitabine tablets|DRUG: Oxaliplatin|DRUG: Cisplatin|DRUG: Paclitaxel|DRUG: Irinotecan|DRUG: Docetaxel|DRUG: 5-FU
Number of patients with Adverse Events (AEs), Up to approximately 2 years|Objective Response Rate (ORR), Up to approximately 2 years
Disease control rate (DCR), Up to approximately 2 years|Duration of Response (DoR), Up to approximately 2 years|Time to response (TTR), Up to approximately 2 years|Progression free survival (PFS), Up to approximately 2 years|Overall survival (OS), Up to approximately 2 years|Maximum observed concentration (Cmax) of AK117 and AK104, The endpoints for assessment of PK include serum concentrations of AK117 and AK104 at different timepoints after study drug administration., From first dose of study drug to last dose of of study drug|Minimum observed concentration (Cmin) of AK117 and AK104 at steady state, The endpoints for assessment of PK include serum concentrations of AK117 and AK104 at different timepoints after study drug administration., From first dose of study drug to last dose of of study drug|Number of subjects who develop detectable anti-drug antibodies (ADAs), The immunogenicity of AK117 and AK104 will be assessed by summarizing the number of subjects who develop detectable anti-drug antibodies (ADAs)., From first dose of study drug through 30 days after last dose of study drug
Phase Ib/II open label, multicenter study to evaluate the efficacy and safety of AK104 (anti-PD-1 and CTLA-4 bispecific antibody) and AK117#AntiCD47 Antibody# combined with or without chemotherapy in advanced malignant tumors